January 15, 2019 05:28 AM EST
Pharma

Aim­mune says US gov­ern­ment shut­down stymied its peanut al­ler­gy drug ap­pli­ca­tion

Natalie Grover

Reporter

As the longest gov­ern­ment shut­down in US his­to­ry en­dures the wrath of law­mak­ers on ei­ther side of the aisle, Aim­mune Ther­a­peu­tics $AIMT will bear the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Keros halts parts of Phase 2 PAH tri­al due to safe­ty, stock tanks 70%

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

Cor­cept’s ALS drug fails to im­prove func­tion in Phase 2 study

Lon­za looks to de­part cap­sule and health in­gre­di­ents as it un­der­goes re­struc­ture

The End­points 100: The biotech in­dus­try braces for Trump 2.0

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times